Anales de la RANM

274 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 Alberto Ortiz An RANM · Año 2020 · número 137 (03) · páginas 270 a 275 ENFERMEDAD RENAL CRÓNICA Y COVID-19 La investigación de los autores está financiada por Sources of support: FIS/Fondos FEDER (PI18/01366, PI19/00815, DTS18/00032, ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071, ISCIII-RETIC REDinREN RD016/0009), Sociedad Española de Nefrología, FRIAT, Comunidad de Madrid en Biomedicina B2017/BMD-3686 CIFRA2- CM, V Premio Jóvenes Investigadores AstraZeneca 2020. 1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Cli- nical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kid- ney Int Suppl 2013; 3: 1–150 2. Perez-Gomez MV, Bartsch LA, Castillo-Rodri- guez E, et al. Clarifying the concept of chronic kidney disease for non-nephrologists. Clin Kid- ney J. 2019;12(2):258-261 3. Jager KJ, Kovesdy C, Langham R, Rosen- berg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwi- de more than 850 million individuals have kidney diseases. Nephrol Dial Transplant. 2019;34(11):1803-1805 4. Foreman KJ, Marquez N, Dolgert A, et al. Fo- recasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative sce- narios for 2016-40 for 195 countries and terri- tories. Lancet. 2018;392(10159):2052-2090 5. Ortiz A, Sanchez-Niño MD, Crespo-Barrio M, et al. The Spanish Society of Nephrology (SE- NEFRO) commentary to the Spain GBD 2016 report: Keeping chronic kidney disease out of sight of health authorities will only magnify the problem. Nefrologia. 2019;39(1):29-34 6. Ortiz A, Covic A, Fliser D, et al. Epidemiolo- gy, contributors to, and clinical trials of mor- tality risk in chronic kidney failure. Lancet. 2014;383(9931):1831-1843 7. Clark A, Jit M, Warren-Gash C, et al. Global, re- gional, and national estimates of the population at increased risk of severe COVID-19 due to un- derlying health conditions in 2020: a modelling study. Lancet Glob Health. 2020;8(8):e1003- e1017 32553130 8. Murray CJ, Ezzati M, Flaxman AD, et al. GBD 2010: a multi-investigator collaboration for glo- bal comparative descriptive epidemiology. Lan- cet. 2012;380(9859):2055-2058 9. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-re- lated death using OpenSAFELY. Nature. 2020;584(7821):430-436 . 32640463 10. Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-Angiotensin-Aldosterone System In- hibitors and Risk of Covid-19. N Engl J Med. 2020;382(25):2441-2448 11. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-Angiotensin-Aldosterone Sys- tem Blockers and the Risk of Covid-19. N Engl J Med. 2020;382(25):2431-2440 12. Holman N, Knighton P, Kar P, et al. Risk fac- tors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020;8(10):823-833 13. Jager KJ, Kramer A, Chesnaye NC, et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020;98(6):1540-1548. 14. Hilbrands LB, Duivenvoorden R, Vart P, Frans- sen CFM for the ERACODA Collaborators. COVID-19-related mortality in kidney trans- plant and dialysis patients: results of the ERA- CODA collaboration. Nephrol Dial Transplant 2020;35(11):1973-1983. 15. Rincón A, Moreso F, López-Herradón A, et al. The keys to control a COVID-19 out- break in a haemodialysis unit. Clin Kidney J. 2020;13(4):542-549. 16. Fernandez-Prado R, Gonzalez-Parra E, Or- tiz A. Often forgotten, transport modality to dialysis may be life-saving. Clin Kidney J. 2020;13(4):510-512. 17. Carriazo S, Kanbay M, Ortiz A. Kidney disease and electrolytes in COVID-19: more than meets the eye. Clin Kidney J. 2020;13(3):274-280 18. Braun F, Lütgehetmann M, Pfefferle S, et al. SARS-CoV-2 renal tropism associates with acu- te kidney injury. Lancet. 2020;396(10251):597- 598. 19. Puelles VG, Lütgehetmann M, Lindenmeyer MT, et al. Multiorgan and Renal Tropism of SARS-CoV-2. N Engl J Med. 2020;383(6):590- 592 20. Couturier A, Ferlicot S, Chevalier K, et al. Indi- rect effects of severe acute respiratory syndro- me coronavirus 2 on the kidney in coronavirus disease patients. Clin Kidney J. 2020;13(3):347- 353. 21. Stock da Cunha T, Gomá-Garcés E, Avello A, et al. The Spectrum of Clinical and Serological Features of COVID-19 in Urban Hemodialysis Patients. J Clin Med. 2020;9(7):2264 22. Lano G, Braconnier A, Bataille S, et al. Risk fac- tors for severity of COVID-19 in chronic dialy- sis patients from a multicentre French cohort. Clin Kidney J. 2020;13(5):878-888 23. Prendecki M, Clarke C, Medjeral-Thomas N, et al. Temporal changes in complement activation in haemodialysis patients with COVID-19 as a predictor of disease progression. Clin Kidney J. 2020;13(5):889-896 24. D'Marco L, Puchades MJ, Romero-Parra M, et al. Coronavirus disease 2019 in chronic kid- ney disease. Clin Kidney J. 2020;13(3):297- 306. 25. Fontana F, Giaroni F, Frisina M, et al. SARS- CoV-2 infection in dialysis patients in northern Italy: a single-centre experience. Clin Kidney J. 2020;13(3):334-339. 26. Wang R, He H, Liao C, et al. Clinical outcomes of hemodialysis patients infected with severe AGRADECIMIENTOS Y FINANCIACIÓN BIBLIOGRAFÍA